Literature DB >> 3352672

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

S J Kish1, K Shannak, O Hornykiewicz.   

Abstract

Autografting of dopamine-producing adrenal medullary tissue to the striatal region of the brain is now being attempted in patients with Parkinson's disease. Since the success of this neurosurgical approach to dopamine-replacement therapy may depend on the selection of the most appropriate subregion of the striatum for implantation, we examined the pattern and degree of dopamine loss in striatum obtained at autopsy from eight patients with idiopathic Parkinson's disease. We found that in the putamen there was a nearly complete depletion of dopamine in all subdivisions, with the greatest reduction in the caudal portions (less than 1 percent of the dopamine remaining). In the caudate nucleus, the only subdivision with severe dopamine reduction was the most dorsal rostral part (4 percent of the dopamine remaining); the other subdivisions still had substantial levels of dopamine (up to approximately 40 percent of control levels). We propose that the motor deficits that are a constant and characteristic feature of idiopathic Parkinson's disease are for the most part a consequence of dopamine loss in the putamen, and that the dopamine-related caudate deficits (in "higher" cognitive functions) are, if present, less marked or restricted to discrete functions only. We conclude that the putamen--particularly its caudal portions--may be the most appropriate site for intrastriatal application of dopamine-producing autografts in patients with idiopathic Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3352672     DOI: 10.1056/NEJM198804073181402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  458 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

2.  Dopamine release and uptake dynamics within nonhuman primate striatum in vitro.

Authors:  S J Cragg; C J Hille; S A Greenfield
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

3.  Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging.

Authors:  Roshan Cools; Luke Clark; Adrian M Owen; Trevor W Robbins
Journal:  J Neurosci       Date:  2002-06-01       Impact factor: 6.167

Review 4.  Functional genomics and psychiatric illness.

Authors:  Wendy Hasenkamp; Scott E Hemby
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

Review 5.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

6.  Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy.

Authors:  Jill R Crittenden; Ippolita Cantuti-Castelvetri; Esen Saka; Christine E Keller-McGandy; Ledia F Hernandez; Lauren R Kett; Anne B Young; David G Standaert; Ann M Graybiel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

7.  Role of a lateralized parietal-basal ganglia circuit in hierarchical pattern perception: evidence from Parkinson's disease.

Authors:  Haline E Schendan; Melissa M Amick; Alice Cronin-Golomb
Journal:  Behav Neurosci       Date:  2009-02       Impact factor: 1.912

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 9.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

10.  Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Authors:  Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.